The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.
Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.
Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.
Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.
Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities Samantha Kurtz - Piper Sandler Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Shagun Singh - RBC Capital Markets Michael Kratky - Leerink Partners Operator Good afternoon. My name is Rob and I will be your conference operator today.
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago.
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.